OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints

By: via Benzinga
Targeted Response Rate Achieved for Plasma Parathyroid Hormone Reduction Favorable Adverse Event Profile Consistent ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.